Florence F. Roussotte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Florence F. Roussotte has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Paul Thompson
Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, California, USA
8 shared publications Katherine L. Narr
Department of Neurology, Brain Mapping Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
7 shared publicationsElizabeth R. Sowell
Department of Pediatrics, Developmental Cognitive Neuroimaging Laboratory (DCNL), University of Southern California, Los Angeles, California
5 shared publicationsBoris A. Gutman
Imaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA
3 shared publications- Catherine Lebel
Department of Radiology, Cumming School of Medicine, University of Calgary
3 shared publications Derrek P. Hibar
Imaging Genetics Center, Institute for Neuroimaging and Informatics, Department of Neurology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA, USA
3 shared publications
Latest Publications
- 1 January 2018
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 26 (1) , 13-22
In Vivo Brain Plaque and Tangle Burden Mediates the Association Between Diastolic Blood Pressure and Cognitive Functioning in Nondemented Adults
- 1 January 2018
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 26 (1) , 13-22
In Vivo Brain Plaque and Tangle Burden Mediates the Association Between Diastolic Blood Pressure and Cognitive Functioning in Nondemented Adults
- Open Access
- 1 April 2017
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 2 (3) , 280-288
The C677T Variant in MTHFR Modulates Associations Between Brain Integrity, Mood, and Cognitive Functioning in Old Age
- 1 April 2017
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 2 (3) , 280-288
Open AccessThe C677T Variant in MTHFR Modulates Associations Between Brain Integrity, Mood, and Cognitive Functioning in Old Age
- 1 January 2016
- Published by Elsevier
- p. 165-175
Polymorphisms in the Delta Opioid Receptor Gene ( OPRD1 ) and Drug Addiction
- 1 January 2016
- Published by Elsevier
- p. 165-175
Polymorphisms in the Delta Opioid Receptor Gene ( OPRD1 ) and Drug Addiction
- 10 December 2014
- Published by Wiley in Alzheimer's & Dementia
- Vol. 11 (10) , 1153-1162
Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion
Introduction: Genetic variants in DAT1, the gene encoding the dopamine transporter (DAT) protein, have been implicated in many brain disorders. In a recent case‐control study of Alzheimer's disease (AD), a regulatory polymorphism in DAT1 showed a significant association with the clinical stages of dementia.Methods: We tested whether this variant was associated with increased AD risk, and with measures of cognitive decline and longitudinal ventricular expansion, in a large sample of elderly participants with genetic, neurocognitive, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative.Results: The minor allele—previously linked with increased DAT expression in vitro—was more common in AD patients than in both individuals with mild cognitive impairment and healthy elderly controls. The same allele was also associated with poorer cognitive performance and faster ventricular expansion, independently of diagnosis.Discussion: These results may be due to reduced dopaminergic transmission in carriers of the DAT1 mutation.
- 10 December 2014
- Published by Wiley in Alzheimer's & Dementia
- Vol. 11 (10) , 1153-1162
Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion
Introduction: Genetic variants in DAT1, the gene encoding the dopamine transporter (DAT) protein, have been implicated in many brain disorders. In a recent case‐control study of Alzheimer's disease (AD), a regulatory polymorphism in DAT1 showed a significant association with the clinical stages of dementia.Methods: We tested whether this variant was associated with increased AD risk, and with measures of cognitive decline and longitudinal ventricular expansion, in a large sample of elderly participants with genetic, neurocognitive, and neuroimaging data from the Alzheimer's Disease Neuroimaging Initiative.Results: The minor allele—previously linked with increased DAT expression in vitro—was more common in AD patients than in both individuals with mild cognitive impairment and healthy elderly controls. The same allele was also associated with poorer cognitive performance and faster ventricular expansion, independently of diagnosis.Discussion: These results may be due to reduced dopaminergic transmission in carriers of the DAT1 mutation.
- 1 June 2014
- Published by Elsevier in Neurobiology of Aging
- Vol. 35 (6) , 1309-1317
The apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging
- 1 June 2014
- Published by Elsevier in Neurobiology of Aging
- Vol. 35 (6) , 1309-1317
The apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging
- Open Access
- 7 May 2014
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 34 (19) , 6537-6545
Combined Effects of Alzheimer Risk Variants in theCLUandApoEGenes on Ventricular Expansion Patterns in the Elderly
The C allele at the rs11136000 locus in the clusterin (CLU) gene is the third strongest known genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent genome-wide association study of LOAD found the strongest evidence of association withCLUat rs1532278, in high linkage disequilibrium with rs11136000. Brain structure and function are related to theCLUrisk alleles, not just in LOAD patients but also in healthy young adults. We tracked the volume of the lateral ventricles across baseline, 1-year, and 2-year follow-up scans in a large sample of elderly human participants (N= 736 at baseline), from the Alzheimer's Disease Neuroimaging Initiative, to determine whether theseCLUrisk variants predicted longitudinal ventricular expansion. The rs11136000 major C allele—previously linked with reducedCLUexpression and with increased risk for dementia—predicted faster expansion, independently of dementia status orApoEgenotype. Further analyses revealed that theCLUandApoErisk variants had combined effects on both volumetric expansion and lateral ventricle surface morphology. The rs1532278 locus strongly resembles a regulatory element. Its association with ventricular expansion was slightly stronger than that of rs11136000 in our analyses, suggesting that it may be closer to a functional variant. Clusterin affects inflammation, immune responses, and amyloid clearance, which in turn may result in neurodegeneration. Pharmaceutical agents such as valproate, which counteract the effects of genetically determined reduced clusterin expression, may help to achieve neuroprotection and contribute to the prevention of dementia, especially in carriers of theseCLUrisk variants.
- 7 May 2014
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 34 (19) , 6537-6545
Open AccessCombined Effects of Alzheimer Risk Variants in theCLUandApoEGenes on Ventricular Expansion Patterns in the Elderly
The C allele at the rs11136000 locus in the clusterin (CLU) gene is the third strongest known genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent genome-wide association study of LOAD found the strongest evidence of association withCLUat rs1532278, in high linkage disequilibrium with rs11136000. Brain structure and function are related to theCLUrisk alleles, not just in LOAD patients but also in healthy young adults. We tracked the volume of the lateral ventricles across baseline, 1-year, and 2-year follow-up scans in a large sample of elderly human participants (N= 736 at baseline), from the Alzheimer's Disease Neuroimaging Initiative, to determine whether theseCLUrisk variants predicted longitudinal ventricular expansion. The rs11136000 major C allele—previously linked with reducedCLUexpression and with increased risk for dementia—predicted faster expansion, independently of dementia status orApoEgenotype. Further analyses revealed that theCLUandApoErisk variants had combined effects on both volumetric expansion and lateral ventricle surface morphology. The rs1532278 locus strongly resembles a regulatory element. Its association with ventricular expansion was slightly stronger than that of rs11136000 in our analyses, suggesting that it may be closer to a functional variant. Clusterin affects inflammation, immune responses, and amyloid clearance, which in turn may result in neurodegeneration. Pharmaceutical agents such as valproate, which counteract the effects of genetically determined reduced clusterin expression, may help to achieve neuroprotection and contribute to the prevention of dementia, especially in carriers of theseCLUrisk variants.
- 16 March 2014
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 9 (2) , 213-222
Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2)
Dopamine D2 receptors mediate the rewarding effects of many drugs of abuse. In humans, several polymorphisms in DRD2, the gene encoding these receptors, increase our genetic risk for developing addictive disorders. Here, we examined one of the most frequently studied candidate variant for addiction in DRD2 for association with brain structure. We tested whether this variant showed associations with regional brain volumes across two independent elderly cohorts, totaling 1,032 subjects. We first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI1). We hypothesized that this addiction-related polymorphism would be associated with structural brain differences in regions previously implicated in familial vulnerability for drug dependence. Then, we assessed the generalizability of our findings by testing this polymorphism in a non-overlapping replication sample of 294 elderly subjects from a continuation of the first ADNI project (ADNI2) to minimize the risk of reporting false positive results. In both cohorts, the minor allele—previously linked with increased risk for addiction—was associated with larger volumes in various brain regions implicated in reward processing. These findings suggest that neuroanatomical phenotypes associated with familial vulnerability for drug dependence may be partially mediated by DRD2 genotype.
- 16 March 2014
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 9 (2) , 213-222
Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2)
Dopamine D2 receptors mediate the rewarding effects of many drugs of abuse. In humans, several polymorphisms in DRD2, the gene encoding these receptors, increase our genetic risk for developing addictive disorders. Here, we examined one of the most frequently studied candidate variant for addiction in DRD2 for association with brain structure. We tested whether this variant showed associations with regional brain volumes across two independent elderly cohorts, totaling 1,032 subjects. We first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI1). We hypothesized that this addiction-related polymorphism would be associated with structural brain differences in regions previously implicated in familial vulnerability for drug dependence. Then, we assessed the generalizability of our findings by testing this polymorphism in a non-overlapping replication sample of 294 elderly subjects from a continuation of the first ADNI project (ADNI2) to minimize the risk of reporting false positive results. In both cohorts, the minor allele—previously linked with increased risk for addiction—was associated with larger volumes in various brain regions implicated in reward processing. These findings suggest that neuroanatomical phenotypes associated with familial vulnerability for drug dependence may be partially mediated by DRD2 genotype.
- 20 October 2013
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 8 (2) , 217-233
Neuroimaging and genetic risk for Alzheimer’s disease and addiction-related degenerative brain disorders
Neuroimaging offers a powerful means to assess the trajectory of brain degeneration in a variety of disorders, including Alzheimer’s disease (AD). Here we describe how multi-modal imaging can be used to study the changing brain during the different stages of AD. We integrate findings from a range of studies using magnetic resonance imaging (MRI), positron emission tomography (PET), functional MRI (fMRI) and diffusion weighted imaging (DWI). Neuroimaging reveals how risk genes for degenerative disorders affect the brain, including several recently discovered genetic variants that may disrupt brain connectivity. We review some recent neuroimaging studies of genetic polymorphisms associated with increased risk for late-onset Alzheimer’s disease (LOAD). Some genetic variants that increase risk for drug addiction may overlap with those associated with degenerative brain disorders. These common associations offer new insight into mechanisms underlying neurodegeneration and addictive behaviors, and may offer new leads for treating them before severe and irreversible neurological symptoms appear.
- 20 October 2013
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 8 (2) , 217-233
Neuroimaging and genetic risk for Alzheimer’s disease and addiction-related degenerative brain disorders
Neuroimaging offers a powerful means to assess the trajectory of brain degeneration in a variety of disorders, including Alzheimer’s disease (AD). Here we describe how multi-modal imaging can be used to study the changing brain during the different stages of AD. We integrate findings from a range of studies using magnetic resonance imaging (MRI), positron emission tomography (PET), functional MRI (fMRI) and diffusion weighted imaging (DWI). Neuroimaging reveals how risk genes for degenerative disorders affect the brain, including several recently discovered genetic variants that may disrupt brain connectivity. We review some recent neuroimaging studies of genetic polymorphisms associated with increased risk for late-onset Alzheimer’s disease (LOAD). Some genetic variants that increase risk for drug addiction may overlap with those associated with degenerative brain disorders. These common associations offer new insight into mechanisms underlying neurodegeneration and addictive behaviors, and may offer new leads for treating them before severe and irreversible neurological symptoms appear.
- 1 August 2013
- Published by Elsevier in Psychiatry Research
- Vol. 213 (2) , 161-168
White matter microstructure abnormalities and executive function in adolescents with prenatal cocaine exposure
- 1 August 2013
- Published by Elsevier in Psychiatry Research
- Vol. 213 (2) , 161-168
White matter microstructure abnormalities and executive function in adolescents with prenatal cocaine exposure
- 21 February 2013
- Published by Wiley in Human Brain Mapping
- Vol. 35 (4) , 1226-1236
A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations
Delta opioid receptors are implicated in a variety of psychiatric and neurological disorders. These receptors play a key role in the reinforcing properties of drugs of abuse, and polymorphisms in OPRD1 (the gene encoding delta opioid receptors) are associated with drug addiction. Delta opioid receptors are also involved in protecting neurons against hypoxic and ischemic stress. Here, we first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer's Disease Neuroimaging Initiative. We hypothesized that common variants in OPRD1 would be associated with differences in brain structure, particularly in regions relevant to addictive and neurodegenerative disorders. One very common variant (rs678849) predicted differences in regional brain volumes. We replicated the association of this single‐nucleotide polymorphism with regional tissue volumes in a large sample of young participants in the Queensland Twin Imaging study. Although the same allele was associated with reduced volumes in both cohorts, the brain regions affected differed between the two samples. In healthy elderly, exploratory analyses suggested that the genotype associated with reduced brain volumes in both cohorts may also predict cerebrospinal fluid levels of neurodegenerative biomarkers, but this requires confirmation. If opiate receptor genetic variants are related to individual differences in brain structure, genotyping of these variants may be helpful when designing clinical trials targeting delta opioid receptors to treat neurological disorders. Hum Brain Mapp 35:1226–1236, 2014.
- 21 February 2013
- Published by Wiley in Human Brain Mapping
- Vol. 35 (4) , 1226-1236
A commonly carried genetic variant in the delta opioid receptor gene, OPRD1, is associated with smaller regional brain volumes: Replication in elderly and young populations
Delta opioid receptors are implicated in a variety of psychiatric and neurological disorders. These receptors play a key role in the reinforcing properties of drugs of abuse, and polymorphisms in OPRD1 (the gene encoding delta opioid receptors) are associated with drug addiction. Delta opioid receptors are also involved in protecting neurons against hypoxic and ischemic stress. Here, we first examined a large sample of 738 elderly participants with neuroimaging and genetic data from the Alzheimer's Disease Neuroimaging Initiative. We hypothesized that common variants in OPRD1 would be associated with differences in brain structure, particularly in regions relevant to addictive and neurodegenerative disorders. One very common variant (rs678849) predicted differences in regional brain volumes. We replicated the association of this single‐nucleotide polymorphism with regional tissue volumes in a large sample of young participants in the Queensland Twin Imaging study. Although the same allele was associated with reduced volumes in both cohorts, the brain regions affected differed between the two samples. In healthy elderly, exploratory analyses suggested that the genotype associated with reduced brain volumes in both cohorts may also predict cerebrospinal fluid levels of neurodegenerative biomarkers, but this requires confirmation. If opiate receptor genetic variants are related to individual differences in brain structure, genotyping of these variants may be helpful when designing clinical trials targeting delta opioid receptors to treat neurological disorders. Hum Brain Mapp 35:1226–1236, 2014.